Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697788 · ClinicalTrials.gov registry record · Phase 2
Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00697788: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00697788 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00697788, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.
Primary Outcome
Looking at hemodynamic response to dexmedetomidine. Mean arterial pressure primary outcome measure.
Interventions
- DRUG Dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-07-16 |
| Est. Completion | 2008-12-30 |
| Phase | Phase 2 |
What the finished NCT00697788 record still lists
NCT00697788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Dexmedetomidine is the first listed.
NCT00697788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00697788 about?
NCT00697788 is a clinical study titled "Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients". Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.
What is the current status of trial NCT00697788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2007-07-16. Estimated completion is 2008-12-30.
What interventions are being tested in trial NCT00697788?
The interventions under investigation include: Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT00697788?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00697788's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI